Related content

Dabigatran etexilate: An alternative to warfarin for patients with nonvalvular atrial fibrillation

By  

JOURNAL OF THE AMERICAN ASSOCIATION OF NURSE PRACTITIONERS (ELECTRONIC), Vol. 27, Iss. 4, 2015-04 ,pp. : 190-196

John Wiley & Sons Inc

Access to resources Recommend Favorite

Hospital length of stay: is rivaroxaban associated with shorter inpatient stay compared to warfarin among patients with non-valvular atrial fibrillation?

By Laliberté François   Pilon Dominic   Raut Monika K.   Nelson Winnie W.   Olson William H.   Germain Guillaume   Schein Jeff R.   Lefebvre Patrick  

Current Medical Research and Opinion, Vol. 30, Iss. 4, 2014-04 ,pp. : 645-653

Informa Healthcare

Access to resources Recommend Favorite

Anticoagulation in patients with non-valvular atrial fibrillation: an evaluation of stability and early factors that predict longer-term stability on warfarin in a large UK population

By Currie Craig J.   McEwan Phil   Emmas Cathy   Morgan Christopher Ll.   Peters John R.  

Current Medical Research and Opinion, Vol. 21, Iss. 12, 2005-12 ,pp. : 1905-1913

Informa Healthcare

Access to resources Recommend Favorite

Heparin bridging in warfarin anticoagulation therapy initiation could increase bleeding in non‐valvular atrial fibrillation patients: a multicenter propensity‐matched analysis

By  

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, Vol. 13, Iss. 2, 2015-02 ,pp. : 182-190

John Wiley & Sons Inc

Access to resources Recommend Favorite

Medical costs in the US of clinical events associated with oral anticoagulant (OAC) use compared to warfarin among non-valvular atrial fibrillation patients ≥75 and <75 years of age, based on the ARISTOTLE, RE-LY, and ROCKET-AF trials

By Deitelzweig Steve   Amin Alpesh   Jing Yonghua   Makenbaeva Dinara   Wiederkehr Daniel   Lin Jay   Graham John  

Journal of Medical Economics, Vol. 16, Iss. 9, 2013-09 ,pp. : 1163-1168

Informa Healthcare

Access to resources Recommend Favorite